CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
18F-FDG PET/CT Imaging +3 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02899377
NCT02899377N/ACompleted

A Pilot Study to Evaluate Molecular Imaging Methods in Primary Sjögren's Syndrome

GlaxoSmithKline·interventional·Posted Sep 14, 2016·Updated Oct 25, 2019

In Brief

A clinical study evaluating 18F-FDG PET/CT Imaging, 11C-MET PET/CT Imaging, and 2 other interventions for Autoimmune Diseases. Completed, enrolled 25 participants across 4 sites.

Detailed Summary

This is a pilot imaging study to determine whether molecular imaging with 18\^F fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), 11\^C-Methionine (MET) PET/CT, and salivary gland magnetic resonance imaging (MRI) with Dotarem (gadoterate meglumine) have the potential to characterize and quantify disease manifestations in primary Sjögren's syndrome (pSS) subjects. This will be achieved by assessing the associations and consistency between the imaging techniques studied, clinical assessments (salivary and tear flow and clinical scores), laboratory biomarkers, and histological findings on minor salivary gland biopsy. In this study, healthy volunteers will be enrolled in Group A and pSS subjects in Group B. The subjects will be required to undergo screening and baseline assessments including unstimulated and stimulated salivary flow and Schirmer's test; an imaging visit (Visit 1); a sample collection visit (Visit 2) for repeat of selected baseline assessments and a minor salivary gland biopsy for pSS subjects only; and a follow-up visit. The total duration of participation in the study will be up to 11 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
CollaboratorsQuintiles, Inc.

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 14, 2016
Enrollment StartNov 18, 2016
Primary CompletionJul 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.8 years ago

Interventions

18F-FDG PET/CT Imagingradiation

pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG

11C-MET PET/CT Imagingradiation

Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes. Other Name:11C-MET

MRI Imaging with intravenous contrast with gadoterate meglumineprocedure

Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.

Minor Salivary gland (labial) biopsyprocedure

A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.